Peginterferon and ribavirin treatment for hepatitis C virus infection

doi:10.3748/wjg.v17.i4.419

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5325)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

414

HTML

4668

Tables (1-2)

243

Sum=5325

Jan 28, 2011 (publication date) through Jan 19, 2025

Times Cited of This Article

Times Cited (39)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jan 28, 2011; 17(4): 419-432
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.419

Table 2 Randomized, controlled trials and cohort studies comparing efficacy of peginterferon α-2a vsα-2b in combination with ribavirin for treatment-naïve patients

Authors	Country	Study design	Peg-IFNα (μg/wk)	Ribavirin (mg/d)	No. of patients	SVR rate (α-2a vsα-2b) (%)	P value
McHutchison et al[27], 2009	USA	RCT, IDEAL study, industry-initiated, multicenter	2a: 180	2a: 1000-1200	2a: 1035¹	40.9 vs 38.0 or 39.8	NS
McHutchison et al[27], 2009		RCT, IDEAL study, industry-initiated, multicenter	2b: 1.0/kg or 1.5/kg	2b: 800-1400	2b: 1016¹ or 1019¹	40.9 vs 38.0 or 39.8
Ascione et al[29], 2010	Italy	RCT, investigator-initiated, single-center	2a: 180	2a: 1000-1200	2a: 160²	68.8 vs 54.4	0.008
Ascione et al[29], 2010		RCT, investigator-initiated, single-center	2b: 1.5	2b: 1000-1200	2b: 160²
Rumi et al[28], 2010	Italy	RCT, MIST study, investigator-initiated, single-center	2a: 180	2a: 1000-1200	2a: 212²	66 vs 54	0.020
Rumi et al[28], 2010		RCT, MIST study, investigator-initiated, single-center	2b: 1.5	2b: 800-1400	2b: 219²
Yenice et al[120], 2006	Turkey	RCT, investigator-initiated, single-center	2a: 180	2a: 800-1200	2a: 37¹	48.6 vs 35.1	NS
Yenice et al[120], 2006		RCT, investigator-initiated, single-center	2b: 1.5	2b: 800-1200	2b: 37¹
Craxi et al[26], 2008	Italy	Prospective, PROBE study, industry-initiated, multicenter	2a: 180	2a: 1000-1200	2a: 663¹	36 vs 29	0.020
Craxi et al[26], 2008		Prospective, PROBE study, industry-initiated, multicenter	2b: 1.5	2b: 1000-1200	2b: 354¹
Witthoeft et al[75], 2008	Germany	Retrospective, PRACTICE study, industry-initiated, multicenter, matched pair	2a: 180	2a: Not stated	2a: 848²	59.3 vs 53.0	0.008
Witthoeft et al[75], 2008			2b: 1.5	2b: Not stated	2b: 848²
Backus et al[25], 2007	USA	Retrospective, United States veterans, government-initiated, multicenter	2a: 180	2a: 1000-1200	2a: 2091²	25 vs 18	< 0.001
Backus et al[25], 2007			2b: 1.5	2b: 800-1400	2b: 3853²

¹Genotype 1 alone;

²Genotypes 1-3 or 1-4. Peg-IFNα: Pegylated interferon α; SVR: Sustained virological response; RCT: Randomized controlled trial; NS: Not significant; IDEAL: Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon Therapy; MIST: Milan Safety Tolerability; PROBE: Pegylated interferons and Real Optimization of Best Efficacy; PRACTICE: Pegylated Interferons and Ribavirin: Analysis of Chronic Hepatitis C Treatment In Centres of Excellence.

Citation: Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 2011; 17(4): 419-432
URL: https://www.wjgnet.com/1007-9327/full/v17/i4/419.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i4.419